QPPV.COM KNOWLEDGE ASSESSMENT

Datopotamab Deruxtecan: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Datopotamab Deruxtecan: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient receiving datopotamab deruxtecan develops cough, dyspnoea and new pulmonary imaging abnormalities. What is the most appropriate pharmacovigilance interpretation?

Assume infection because respiratory symptoms are nonspecific Assume tumour progression because the patient has metastatic disease Evaluate suspected ILD/pneumonitis while investigating infection, embolism, progression, radiation effects and other pneumotoxic therapy Code only 'respiratory disorder' and wait for the next periodic report

Question 2 of 10 Which set of administration details is most important for reconstructing a datopotamab deruxtecan exposure?

Exact dose, infusion date, dose number, interval and any dose reduction or delay Only the patient's tumour marker level Only the name of the dispensing pharmacy Only whether the patient previously received endocrine therapy

Question 3 of 10 Which information is particularly important when medically reviewing a suspected ILD/pneumonitis case?

Only the patient's tumour receptor status CT findings, oxygen requirement, infectious investigations, corticosteroid use, treatment interruption or discontinuation and outcome Only whether the patient experienced alopecia Only the number of prior oral medicines

Question 4 of 10 Why is the membrane permeability of released DXd important when interpreting both efficacy and toxicity?

It prevents the payload from entering tumour cells It allows local diffusion into neighbouring cells, supporting bystander killing but also potentially contributing to tissue toxicity It ensures that only TROP2-positive cells are exposed It converts the ADC into an antibody-independent immunotherapy

Question 5 of 10 Which report most strongly supports meaningful assessment of a suspected ocular adverse reaction?

The patient had an 'eye problem' with no further details The report includes visual symptoms, laterality, contact-lens use, baseline eye disease, slit-lamp or fluorescein findings and ophthalmology diagnosis The report records only the date of the next cancer treatment The report states that the patient had no gastrointestinal symptoms

Question 6 of 10 Why should safety data from the HR-positive/HER2-negative and first-line TNBC settings not automatically be pooled without stratification?

The two settings use different biological targets Treatment line and patient characteristics influence prior toxicity, marrow reserve, comorbidity and background treatment Pooling is prohibited for all ADCs regardless of indication The ADC has a different chemical name in each breast-cancer subtype

Question 7 of 10 Why should respiratory cases be medically reviewed rather than assessed solely through broad coding terms?

Respiratory symptoms are never associated with anticancer therapy Nonspecific terms such as pneumonia or cough may conceal clinically important ILD/pneumonitis Medical review is needed only for medication errors Broad coding automatically establishes the diagnosis

Question 8 of 10 Which information is most important in a pregnancy exposure report involving datopotamab deruxtecan?

Gestational timing, dose dates, co-exposures, maternal cancer status and fetal or neonatal outcome Only the patient's age at diagnosis Only whether the tumour was TROP2-positive Only whether the patient experienced dry eye

Question 9 of 10 Which information is most relevant when evaluating a suspected infusion reaction?

Latency from infusion start, symptoms and vital signs, interruption, treatment and outcome on re-exposure Only the patient's baseline eye examination Only whether the tumour expressed TROP2 Only the final survival outcome

Question 10 of 10 Which sequence most accurately describes the principal intracellular mechanism of datopotamab deruxtecan?

TROP2 binding, internalisation, linker cleavage, DXd release and topoisomerase-I inhibition Topoisomerase-I inhibition at the cell surface followed by antibody synthesis TROP2 degradation, extracellular payload activation and immune-complex formation DNA alkylation by the intact antibody before cellular uptake

Datopotamab Deruxtecan: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Cookie Settings